1:55PM ET 6/10/2022 MT NewswiresCFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...
10:15AM ET 6/06/2022 MT NewswiresNeurocrine Biosciences (NBIX) has an average rating of outperform and price targets ranging from $75 to $150, according to analysts polled by Capital IQ....
3:04AM ET 5/25/2022 MT NewswiresNeurocrine Biosciences (NBIX) entered into privately negotiated transactions to repurchase about $179.4 million of its existing 2.25% convertible senior...
3:42AM ET 5/13/2022 MT NewswiresNeurocrine Biosciences (NBIX) said late Thursday the US Food and Drug Administration granted an orphan drug designation to valbenazine for the potential...